Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Hubbard

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Journal of Applied Physiology (Bethesda, Md. : 1985)|August 1, 1993
Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluidA Gillissen, P Birrer, N G McElvaney, et al.
The Journal of International Medical Research|January 24, 2002
Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hipA J Kivitz, R W Moskowitz, E Woods, et al.
The American Journal of Gastroenterology|April 24, 2001
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritisJ L Goldstein, P Correa, W W Zhao, et al.
Lancet (London, England)|February 16, 1991
Aerosol alpha 1-antitrypsin treatment for cystic fibrosisN G McElvaney, R C Hubbard, P Birrer, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1990
Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosolR Buhl, C Vogelmeier, M Critenden, et al.
The American Journal of Gastroenterology|August 5, 2000
Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitorJ L Goldstein, F E Silverstein, N M Agrawal, et al.
The Journal of Clinical Investigation|June 1, 1991
Expression of the secretory leukoprotease inhibitor gene in epithelial cellsT Abe, N Kobayashi, K Yoshimura, et al.
The New England Journal of Medicine|March 19, 1992
A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosisR C Hubbard, N G McElvaney, P Birrer, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 17, 2008
Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trialG W Williams, R E Ettlinger, E M Ruderman, et al.
Arthritis and Rheumatism|September 29, 1998
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effectsL S Simon, F L Lanza, P E Lipsky, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Journal of Applied Physiology (Bethesda, Md. : 1985)|August 1, 1993
Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluidA Gillissen, P Birrer, N G McElvaney, et al.
The Journal of International Medical Research|January 24, 2002
Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hipA J Kivitz, R W Moskowitz, E Woods, et al.
The American Journal of Gastroenterology|April 24, 2001
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritisJ L Goldstein, P Correa, W W Zhao, et al.
Lancet (London, England)|February 16, 1991
Aerosol alpha 1-antitrypsin treatment for cystic fibrosisN G McElvaney, R C Hubbard, P Birrer, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1990
Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosolR Buhl, C Vogelmeier, M Critenden, et al.
The American Journal of Gastroenterology|August 5, 2000
Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitorJ L Goldstein, F E Silverstein, N M Agrawal, et al.
The Journal of Clinical Investigation|June 1, 1991
Expression of the secretory leukoprotease inhibitor gene in epithelial cellsT Abe, N Kobayashi, K Yoshimura, et al.
The New England Journal of Medicine|March 19, 1992
A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosisR C Hubbard, N G McElvaney, P Birrer, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 17, 2008
Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trialG W Williams, R E Ettlinger, E M Ruderman, et al.
Arthritis and Rheumatism|September 29, 1998
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effectsL S Simon, F L Lanza, P E Lipsky, et al.
Pageof 6